109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
sCD36 作为 2 型糖尿病相关肝细胞癌进展和复发的生物标志物
Authors Dai W, Yang F, Guo F, Ding Y, He D, Zhang J, Guo Y, Gao Y, Xiao A
Received 3 September 2025
Accepted for publication 31 October 2025
Published 14 November 2025 Volume 2025:12 Pages 2541—2552
DOI https://doi.org/10.2147/JHC.S565006
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Imam Waked
Weiwei Dai,1,* Fan Yang,2,* Furao Guo,1 Yuling Ding,1 Deying He,1 Jiajia Zhang,1 Ying Guo,1 Yingying Gao,1 Anhua Xiao1,3,4
1Department of Clinical Laboratory, Affiliated Banan Hospital of Chongqing Medical University, Chongqing, 401320, People’s Republic of China; 2College of Clinical Medicine, Jiamusi University, Heilongjiang, 154007, People’s Republic of China; 3Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the second Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, People’s Republic of China; 4School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 40016, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Anhua Xiao, Email 138813@hospital.cqmu.edu.cn Yingying Gao, Email happygaoyingying@163.com
Background: To evaluate the relationship between soluble CD36 (sCD36) and type 2 diabetes mellitus complicated by hepatocellular carcinoma (T2DM-HCC), and to explore its potential clinical prognostic value.
Methods: A prospective study was conducted enrolling newly diagnosed T2DM-HCC patients from two medical centers, along with control groups including healthy individuals (HC), T2DM patients, and HCC patients. Clinical, biochemical, and pathological data were collected. Serum sCD36 levels were measured by ELISA. Univariate and multivariate analyses were used to identify recurrence risk factors, and ROC analysis was performed to evaluate diagnostic performance.
Results: Among 258 participants, the T2DM-HCC group exhibited the highest sCD36 levels, impaired liver function, lower platelets, and mild chronic inflammation. In this group, sCD36 levels positively correlated with tumor stage, size, and proliferation. In univariable analysis, it was associated with postoperative recurrence (OR = 2.57, 95% CI: 0.68– 9.67). The predictive ability of sCD36 for recurrence (AUC = 0.86) was comparable to AFP (AUC = 0.89), while their combination showed the highest accuracy (AUC = 0.94).
Conclusion: sCD36 is associated with tumor progression in T2DM-HCC patients and serves as an independent risk factor for recurrence. To the best of our knowledge, this is the first study to identify sCD36 as a critical clinical biomarker for disease progression in T2DM-HCC, with strong potential for clinical application.
Trial Registration: This study was registered in September 2024 with the Chinese Clinical Trial Registry (ChiCTR), registration number: ChiCTR2400089651.
Keywords: sCD36, T2DM, hepatocellular carcinoma, predictive, prognosis
1Department of Clinical Laboratory, Affiliated Banan Hospital of Chongqing Medical University, Chongqing, 401320, People’s Republic of China; 2College of Clinical Medicine, Jiamusi University, Heilongjiang, 154007, People’s Republic of China; 3Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the second Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, People’s Republic of China; 4School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 40016, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Anhua Xiao, Email 138813@hospital.cqmu.edu.cn Yingying Gao, Email happygaoyingying@163.com
Background: To evaluate the relationship between soluble CD36 (sCD36) and type 2 diabetes mellitus complicated by hepatocellular carcinoma (T2DM-HCC), and to explore its potential clinical prognostic value.
Methods: A prospective study was conducted enrolling newly diagnosed T2DM-HCC patients from two medical centers, along with control groups including healthy individuals (HC), T2DM patients, and HCC patients. Clinical, biochemical, and pathological data were collected. Serum sCD36 levels were measured by ELISA. Univariate and multivariate analyses were used to identify recurrence risk factors, and ROC analysis was performed to evaluate diagnostic performance.
Results: Among 258 participants, the T2DM-HCC group exhibited the highest sCD36 levels, impaired liver function, lower platelets, and mild chronic inflammation. In this group, sCD36 levels positively correlated with tumor stage, size, and proliferation. In univariable analysis, it was associated with postoperative recurrence (OR = 2.57, 95% CI: 0.68– 9.67). The predictive ability of sCD36 for recurrence (AUC = 0.86) was comparable to AFP (AUC = 0.89), while their combination showed the highest accuracy (AUC = 0.94).
Conclusion: sCD36 is associated with tumor progression in T2DM-HCC patients and serves as an independent risk factor for recurrence. To the best of our knowledge, this is the first study to identify sCD36 as a critical clinical biomarker for disease progression in T2DM-HCC, with strong potential for clinical application.
Trial Registration: This study was registered in September 2024 with the Chinese Clinical Trial Registry (ChiCTR), registration number: ChiCTR2400089651.
Keywords: sCD36, T2DM, hepatocellular carcinoma, predictive, prognosis